Mengting Liao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5957998/publications.pdf Version: 2024-02-01



MENCTING LIAO

#	Article	IF	CITATIONS
1	Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. Lung Cancer, 2019, 138, 88-94.	2.0	54
2	Laparoscopic versus open gastrectomy for gastric cancer. World Journal of Surgical Oncology, 2020, 18, 20.	1.9	41
3	Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 1649.	2.8	32
4	Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer. Advances in Therapy, 2020, 37, 2116-2126.	2.9	24
5	Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1141-1147.	4.9	23
6	Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma. Cancer Medicine, 2020, 9, 1451-1461.	2.8	20
7	The prognostic and clinicopathologic characteristics of CD147 and esophagus cancer: A meta-analysis. PLoS ONE, 2017, 12, e0180271.	2.5	17
8	Prognostic Implications of Metabolism Related Gene Signature in Cutaneous Melanoma. Frontiers in Oncology, 2020, 10, 1710.	2.8	16
9	A novel predictive model incorporating immune-related gene signatures for overall survival in melanoma patients. Scientific Reports, 2020, 10, 12462.	3.3	16
10	First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis. Cost Effectiveness and Resource Allocation, 2021, 19, 77.	1.5	15
11	Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China. Journal of Medical Economics, 2019, 22, 584-592.	2.1	13
12	eEF2K promotes PD-L1 stabilization through inactivating GSK3Î ² in melanoma. , 2022, 10, e004026.		11
13	Development and clinical application of a rapid SARSâ€CoVâ€2 antibody test strip: A multiâ€center assessment across China. Journal of Clinical Laboratory Analysis, 2021, 35, e23619.	2.1	10
14	Distinguishing Hepatocellular Carcinoma From Hepatic Inflammatory Pseudotumor Using a Nomogram Based on Contrast-Enhanced Ultrasound. Frontiers in Oncology, 2021, 11, 737099.	2.8	3
15	Cost-effectiveness of tyrosine kinase inhibition in first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer Journal of Clinical Oncology, 2019, 37, e20504-e20504.	1.6	1
16	Cost-effectiveness for metastatic colorectal cancer Journal of Clinical Oncology, 2019, 37, e15003-e15003.	1.6	0